Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON39359
NL-OMON39359
Completed
Phase 3

The effect of botulinum toxin type A injections in the m. rectus femoris in stroke patients presenting with stiff knee gait - Botulinum toxin type A injections in stiff knee gait

Revalidatiecentrum Het Roessingh0 sites26 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsstiff knee gaitstiff-legged knee1000796310057166

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
stiff knee gait
Sponsor
Revalidatiecentrum Het Roessingh
Enrollment
26
Status
Completed
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
Revalidatiecentrum Het Roessingh

Eligibility Criteria

Inclusion Criteria

  • •age over 18 years
  • •6 months post stroke
  • •patient walks with a stiff knee gait caused by an overactivity of the m. rectus femoris
  • •able to walk independent
  • •overactivity of the m. rectus femoris, established with EMG\-measures

Exclusion Criteria

  • •presence of other constraints in joints who impede walking
  • •neurological problems not causes by a Cerebro Vascular Accident
  • •patient walks with a diminished knee flexion as a result of an orthopedic cause
  • •myasthenia gravis or Eaton\-Lambert syndrome
  • •progressive clinical picture which influence the gait pattern
  • •use of amfotericine B en/of amsacrine
  • •pregnancy / nursing mothers

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, Not Recruiting
N/A
The effect of botulinum toxin type A injections in the m. rectus femoris in stroke patients presenting with a stiff knee gait. - Botulinum toxin type A injections in stiff knee gaitStroke patients with stiff knee gait. Stiff knee gait is characterized as a diminished knee flexion during swing phase of gait. It is common in stroke patients.
EUCTR2009-018226-29-NL26
Completed
Phase 2
botulinum toxin type A and diabetic neuropathyDiabeticr polyneuropathy.Type 2 diabetes mellitus with diabetic polyneuropathyE10.42
IRCT20190129042540N1Rafsanjan University of Medical Sciences50
Not Yet Recruiting
N/A
The effect of botulinum toxin-A(BTX-A) injection for equinovarus deformity in children with unilateral cerebral palsy.Diseases of the nervous system
KCT0000530Yonsei University Health System, Severance Hospital30
Recruiting
N/A
Effect of botulinum toxin (BoNT-A) injections on intrinsic and reflexive contributions to ankle joint resistance for patients with spasticitySpinal Cord Injury and Stroke
NL-OMON26235Sint Maartenskliniek Research10
Not Yet Recruiting
N/A
Effect of botulinum toxin (BoNT-A) injections on intrinsic and reflexive contributions to ankle joint resistance for patients with spasticity.
NL-OMON48057Stichting Sint Maartenskliniek10